Table 5 Brief list of recent metallic based drug delivery explored for cancer therapeutics
From: Nanocrystals: an emerging paradigm for cancer therapeutics
Metal | Conjugating drug | Cell lines | IC50 value | Proposed MOA | Reference |
|---|---|---|---|---|---|
Gold | Docetaxel | Lung cancer cell line (H520) | 25 μm | Cell disruption and apoptosis | [168] |
Silver | Epirubicin | HepG2 cells | 1.92 μg/mL | – | [169] |
Copper | Paclitaxel | Drug-resistant prostate cancer cell | 85, 172, and 193Â nM | Inhibition of proteasome/poly-Ub protein degradation pathway by targeting the NPL4 protein | [170] |
Gold and iron | Doxorubicin | HeLa cancer cells | 2.3 μg/mL | Cytoplasmic internalization and cell death | [171] |
Silver | Methotrexate | Breast cancer cells MCF-7 | 258.6 μg/mL | Blocks the synthesis to tetrahydrofolate | [172] |
Silver | Acety-lshikonin and beta-dimethyl-acrylshikonin | Human chronic myeloid leukaemia | 100Â nM | ROS induced toxicity | [173] |
Gold | Doxorubicin | Glioma carcinoma cell line (LN 229) | 4 μg/mL | DNA intercalation and cell death | [174] |